This document relates to conjugates of TNF inhibitors or derivatives thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.

Provided are recombinant Factor VIII proteins, e.g., human Factor VIII proteins with heterologous moieties inserted into flexible permissive loops located in the Factor VIII A domains, while retaining the procoagulant activity of Factor VIII.

Provided are recombinant Factor VIII proteins, e.g., human Factor VIII proteins with heterologous moieties inserted into flexible permissive loops located in the Factor VIII A domains, while retaining the procoagulant activity of Factor VIII.

The present invention relates to the treatment of hemophilia A, in particular to means and methods for subcutaneous administration of Factor VIII (FVIII) proteins. More specifically, the invention relates to FVIII proteins comprising at least one albumin binding domain, which could be shown to have a high bioavailability after subcutaneous administration, in particular, for use in subcutaneous administration to a subject with hemophilia A. The invention also relates to the use of further agents enhancing the bioavailability of FVIII proteins comprising at least one albumin binding domain after subcutaneous administration of such FVIII proteins, in articular human albumin, hyaluronidase and derivatives thereof. The invention also relates to pharmaceutical compositions, combined administration, combined preparations, packages and kits.

The present invention relates to the treatment of hemophilia A, in particular to means and methods for subcutaneous administration of Factor VIII (FVIII) proteins. More specifically, the invention relates to FVIII proteins comprising at least one albumin binding domain, which could be shown to have a high bioavailability after subcutaneous administration, in particular, for use in subcutaneous administration to a subject with hemophilia A. The invention also relates to the use of further agents enhancing the bioavailability of FVIII proteins comprising at least one albumin binding domain after subcutaneous administration of such FVIII proteins, in articular human albumin, hyaluronidase and derivatives thereof. The invention also relates to pharmaceutical compositions, combined administration, combined preparations, packages and kits.

This document relates to conjugates of a biologically active molecule or a derivative thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.

This document relates to conjugates of a biologically active molecule or a derivative thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.

The present invention provides multi-armed high MW polymers containing hydrophilic groups conjugated to Factor VIII, and methods of preparing such polymers.

The present invention provides multi-armed high MW polymers containing hydrophilic groups conjugated to Factor VIII, and methods of preparing such polymers.

The invention relates to chemically as well as physically stable kits and compositions comprising polypeptides, in particular Factor VII or Factor VII-related polypeptides, such that these compositions can be stored, handled and used at room temperature.